Ho Allen S, Wang Lu, Palmer Frank L, Yu Changhong, Toset Arnbjorn, Patel Snehal, Kattan Michael W, Tuttle R Michael, Ganly Ian
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ann Surg Oncol. 2015 Aug;22(8):2700-6. doi: 10.1245/s10434-014-4208-2. Epub 2014 Nov 4.
Medullary thyroid cancer (MTC) is a rare thyroid cancer accounting for 5 % of all thyroid malignancies. The purpose of our study was to design a predictive nomogram for cancer-specific mortality (CSM) utilizing clinical, pathological, and biochemical variables in patients with MTC.
MTC patients managed entirely at Memorial Sloan-Kettering Cancer Center between 1986 and 2010 were identified. Patient, tumor, and treatment characteristics were recorded, and variables predictive of CSM were identified by univariable analyses. A multivariable competing risk model was then built to predict the 10-year cancer specific mortality of MTC. All predictors of interest were added in the starting full model before selection, including age, gender, pre- and postoperative serum calcitonin, pre- and postoperative CEA, RET mutation status, perivascular invasion, margin status, pathologic T status, pathologic N status, and M status. Stepdown method was used in model selection to choose predictive variables.
Of 249 MTC patients, 22.5 % (56/249) died from MTC, whereas 6.4 % (16/249) died secondary to other causes. Mean follow-up period was 87 ± 67 months. The seven variables with the highest predictive accuracy for cancer specific mortality included age, gender, postoperative calcitonin, perivascular invasion, pathologic T status, pathologic N status, and M status. These variables were used to create the final nomogram. Discrimination from the final nomogram was measured at 0.77 with appropriate calibration.
We describe the first nomogram that estimates cause-specific mortality in individual patients with MTC. This predictive nomogram will facilitate patient counseling in terms of prognosis and subsequent clinical follow up.
髓样甲状腺癌(MTC)是一种罕见的甲状腺癌,占所有甲状腺恶性肿瘤的5%。我们研究的目的是利用MTC患者的临床、病理和生化变量设计一个癌症特异性死亡率(CSM)的预测列线图。
确定1986年至2010年间在纪念斯隆凯特琳癌症中心完全接受治疗的MTC患者。记录患者、肿瘤和治疗特征,并通过单变量分析确定CSM的预测变量。然后建立多变量竞争风险模型来预测MTC的10年癌症特异性死亡率。在选择之前,将所有感兴趣的预测因子添加到初始完整模型中,包括年龄、性别、术前和术后血清降钙素、术前和术后癌胚抗原、RET突变状态、血管周围侵犯、切缘状态、病理T分期、病理N分期和M分期。在模型选择中采用逐步回归法选择预测变量。
249例MTC患者中,22.5%(56/249)死于MTC,而6.4%(16/249)死于其他原因。平均随访期为87±67个月。对癌症特异性死亡率预测准确性最高的七个变量包括年龄、性别、术后降钙素、血管周围侵犯、病理T分期、病理N分期和M分期。这些变量用于创建最终的列线图。最终列线图的辨别力经适当校准后为0.77。
我们描述了第一个估计个体MTC患者病因特异性死亡率的列线图。这种预测列线图将有助于在预后和后续临床随访方面为患者提供咨询。